Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 4/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583118 | 0.92 | SMN1; SMN2 (0.40) | GRIN2BPDE4BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2338938 | 0.92 | SMN1; SMN2 (0.40) | GRIN2BPDE4BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1037741 | 0.90 | NPC1 (0.39) | MMP9MMP1MMP3MMP7MMP13 | |
| SCHEMBL2344278 | 0.89 | NPC1 (0.41) | MMP9MMP1MMP3MMP7MMP13 | |
| SCHEMBL2338996 | 0.88 | RORC (0.38) | MMP9MMP1MMP3MMP7MMP13 | |
| SCHEMBL3268191 | 0.88 | FAAH (0.37) | GRIN2BTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4583065 | 0.88 | FAAH (0.37) | GRIN2BTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2340534 | 0.85 | REN (0.46) | — | |
| SCHEMBL4583364 | 0.85 | REN (0.46) | — | |
| SCHEMBL2339949 | 0.84 | PPARG (0.40) | TP53MDM2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776359-B1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-27 | — | — | US | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1776359-A2 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006005741-A2 | PIPERDINE DERIVATIVES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | REN, AGTR1, ACE | MMP9 483/4885MMP1 271/4885MMP3 405/4885 |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | MMP9 107/4885MMP1 284/4885MMP3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.